Remdesivir Risk Versus Benefits Assessment

Drug Trials & Reports

Several reports undertaken into the adverse events of remdesivir conclude remdesivir causes a long list of adverse effects, the most critical being a 53% mortality rate. Remdesivir also causes kidney and liver injury.

In contrast, following a drug trial in February 2020, the only reported benefit remdesivir offered was a possible reduction in hospitalisation by 4 days. That report stated deaths occurred from remdesivir during the drug trial, however the mortality statistics were ignored, and mortality information kept from the world.

In consideration of risk versus benefit, it is incomprehensible any doctor would elect to inject a toxic poison that leads to 53% death, and/or kidney and liver injury where the only benefit may be a reduction of 4 days in hospital.

A poison is a substance that can cause death or injury. Remdesivir causes injury and death. Remdesivir is a poison.

Frank died with almost all of the published adverse effects of remdesivir, including death, multi organ failure, kidney failure, acute kidney injury, deep vein thrombosis, bruising and swelling to his face, body, lips and eyes.

 

Benefits of Remdesivir

BENEFIT: 4 days less in hospital

Following a drug trial for covid in February 2020, the only reported benefit of remdesivir is that it may reduce hospitalisation from 15 days to 11 days.

Mortality that resulted in the drug trail was ignored. As such, an entirely false representation of remdesivir was issued to the world.

In October 2020 The World Health Organisation (WHO) said remdesivir had “little or no effect in preventing death from COVID-19 or reducing time in hospital.”

 

Adverse Effects of Remdesivir

ADVERSE EFFECTS: Death, multi-organ failure, liver failure, kidney injury, +++++

The US National Institutes of Health (NIH) National Library of Medicine provides several remdesivir drug trial reports on its website. Links to the referenced reports are provided below.

On 22 May 2020 Drugs In Context (DIC) published a report titled“The journey of remdesivir: from Ebola to COVID-19”. The report was completed on 14 April 2020. The report outlines results of four drugs trialled to treat ebola. Remdesivir resulted in the highest death rate of the four drugs, with a death rate of 53.1%.

Page 4 the report states, “At day 28, mortality rates were: remdesivir (53.1%)”

NIAID was involved in, and provided funding for, the ebola drug trials, and as such was aware of the 53% dealth rate of remdesivir.

On 22 July 2020 Biomed Pharmacother published a report titled, “Safety profile of the antiviral drug remdesivir: An update”. The report provides a list of adverse events of remdesivir and the number of events (shown as a percentage below):

  1. increased hepatic enzyme 25% (hepatitis or liver disease);

  2. respiratory failure 4%;

  3. pneumothorax 4% (collapsed lung - air leaks into the space between lungs and chest wall];

  4. hypotension: 8% (high blood pressure);

  5. atrial fibrillation 6% (irregular heart rate - heart’s upper chambers beat out of coordination with the lower chamber);

  6. cardiac arrest 1%;

  7. renal impairment 8% [kidneys lose ability to remove waste);

  8. acute kidney injury 6%;

  9. hematuria 4% (blood in urine); and

  10. constipation, nausea, diarrhea, and gastroparesis.

The report also states, “Other adverse effects. Transient rise in serum amylase was reported in an Ebola-infected patient treated with remdesivir. Grein et al.’s study mentioned rash, multiple-organ-dysfunction syndrome, deep-vein thrombosis, delirium, septic shock, pyrexia as adverse events occurred in remdesivir recipients. Adverse events related to hematologic, circulatory, endocrine and other systems were also detected in the remdesivir group in the RCT in China.”

On 24 October 2020 Cureus published a report titled “Cardiac Adverse Events with Remdesivir in COVID 19 Infection”. The report states “Adverse effects are common with remdesivir, but few studies exist that focus on remdesivir and its effects on the cardiovascular system. Out of a study of 53 patients receiving remdesivir, 32 patients (60%) experienced adverse events during follow-up. These adverse events were increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension. Adverse events were more common for those on mechanical ventilation compared to those that were not.”

Queensland Health issued a document titled “Patient Information Remdesivir (Veklury)” which states remdesivir can cause swelling of the face, lips, tongue and other parts ofd the body, and severe skin rash including, itching and hives and nausea and vomiting.